top
Search terms
Results 1 - 5 of 5 - ordered by :
Ehjcvp

Despite treatments for secondary prevention, patients with prior myocardial infarction (MI) remain at high risk for recurrent thrombotic events.1 The addition of a P2Y12 receptor antagonist to ...

European Heart Journal - Cardiovascular Pharmacotherapy, EDITORIAL, Giulia Magnani, Marc P. Bonaca, Marc S. Sabatine

Date : 01/10/2015 Item size : 188203 bytes
Ehjcvp

In this issue of European Heart Journal Cardiovascular Pharmacology a substudy of the Italian EYESHOT Registry focused on medically managed patients is published.1 In it, the authors describe the ...

European Heart Journal - Cardiovascular Pharmacotherapy, EDITORIAL, Héctor Bueno

Date : 01/07/2015 Item size : 219771 bytes
Ehjcvp

[...]anti-GPIIb/IIIa agents are used in conditions such as acute coronary syndrome undergoing percutaneous intervention where the thrombotic tendency of human body become extremely high.1,2 Since the ...

European Heart Journal - Cardiovascular Pharmacotherapy, EDITORIAL, Shinichi Goto, Shinya Goto

Date : 01/01/2015 Item size : 149314 bytes
Ehjcvp

New oral anticoagulants are used in atrial fibrillation (AF) patients to prevent strokes in the primary and secondary prevention settings.1,2 Since AF are reported to be an independent risk factor ...

European Heart Journal - Cardiovascular Pharmacotherapy, EDITORIALS, Shinichi Goto, Shinya Goto

Date : 01/04/2015 Item size : 186244 bytes
Ehjcvp

Anticoagulant agents have strong potential to prevent thrombotic events but have a larger risk for serious bleeding complications, as shown in previous clinical trials.4 Antiplatelet agents are ...

European Heart Journal - Cardiovascular Pharmacotherapy, Invited Editorial, Kengo Ayabe, Shinya Goto

Date : 01/01/2017 Item size : 189745 bytes